Sarepta Therapeutics (SRPT) option implied volatility elevated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Nasdaq, S&P 500 edge lower as tech stocks drop; focus on Mideast conflict
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices fall to one-week low after US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Taiwan Semi (TSM) PT Raised to $530 at Needham
Evercore on Sarepta (SRPT) Post Stat News Article: 'probably sets up for the adcomm briefing documents and tone to be somewhat more negative'
April 13, 2023 10:39 AM EDTEvercore ISI analyst Gavin Clark-Gartner reiterated an Outperform rating and $149.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "The STAT article from this morning (HERE) is a must-read. To briefly summarize: the market had thought SRPTs... More
